LAG3 and melanoma: Recent findings published on anti LAG-3 agent relatlimab have opened a completely new perspective on metastatic melanoma treatment with really encouraging data in terms of PFS that, if confirmed in OS, may lead to a new standard of treatment both for WT and BRAF mutated melanoma [34].